Evaluation of short-term effectiveness of eight targeted agents combined with chemotherapy for treating esophageal-gastric junction adenocarcinoma: A network meta-analysis. (Q48124426)

From Wikidata

Jump to navigation Jump to search

scientific article published on 14 July 2017

Language	Label	Description	Also known as
English	Evaluation of short-term effectiveness of eight targeted agents combined with chemotherapy for treating esophageal-gastric junction adenocarcinoma: A network meta-analysis.	scientific article published on 14 July 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28708307 AND SRC:MED&resulttype=core&format=json

25 March 2020

Evaluation of short-term effectiveness of eight targeted agents combined with chemotherapy for treating esophageal-gastric junction adenocarcinoma: A network meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28708307 AND SRC:MED&resulttype=core&format=json

25 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28708307 AND SRC:MED&resulttype=core&format=json

25 March 2020

author name string

Chen Yu

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28708307 AND SRC:MED&resulttype=core&format=json

25 March 2020

Wei-Bing Li

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28708307 AND SRC:MED&resulttype=core&format=json

25 March 2020

Zhi-Peng Li

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28708307 AND SRC:MED&resulttype=core&format=json

25 March 2020

Nan Xu

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28708307 AND SRC:MED&resulttype=core&format=json

25 March 2020

publication date

5 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28708307 AND SRC:MED&resulttype=core&format=json

25 March 2020

Journal of Cellular Biochemistry

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28708307 AND SRC:MED&resulttype=core&format=json

25 March 2020

119

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28708307 AND SRC:MED&resulttype=core&format=json

25 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28708307 AND SRC:MED&resulttype=core&format=json

25 March 2020

1183-1192

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28708307 AND SRC:MED&resulttype=core&format=json

25 March 2020

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Treatment options in patients with metastatic gastric cancer: current status and future perspectives

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

c-Met targeting in advanced gastric cancer: An open challenge.

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Incidence and management of edema associated with trebananib (AMG 386).

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Bayesian methods for evidence synthesis in cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Use of indirect and mixed treatment comparisons for technology assessment

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Strategy for intention to treat analysis in randomised trials with missing outcome data

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Assessing publication bias in meta-analyses in the presence of between-study heterogeneity

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Graphical tools for network meta-analysis in STATA.

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2.

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Ramucirumab: a novel antiangiogenic agent.

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Magic bullets from llamas

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

1 reference

https://api.crossref.org/works/10.1002/JCB.26288

21 January 2018

Identifiers

10.1002/JCB.26288

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28708307 AND SRC:MED&resulttype=core&format=json

25 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28708307 AND SRC:MED&resulttype=core&format=json

25 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48124426&oldid=1142511087"